LONDON (Alliance News) - AstraZeneca PLC said Tuesday its research and development arm MedImmune has teamed up with US biotechnology company Advaxis Inc for a clinical trial combining MedImmune's MED14736 compound with Advaxis' ADSX-HPV.
The two treatments are both immunotherapies, which use the body's immune system to treat cancer, the company said.
MED14736 is an anti-PD-L1 immune checkpoint inhibitor which blocks a signal that helps tumours avoid detection by the immune system. ADSX-HPV, for the treatment of human papillomavirus associated cervical cancer and head and neck cancer, can enhance the ability of immune cells to combat a tumour.
AstraZeneca said that preclinical evidence suggests a combined treatment could enhance overall anti-tumour response.
Under a clinical trial collaboration agreement, the two companies will evaluate the combined treatment for human papillomavirus associated cervical cancer and squamous cell carcinoma of the head and neck. A Phase I trial will establish a recommended does regimen, and a Phase II trial will assess safety and efficacy.
Advaxis will fund and conduct the study.
Shares in AstraZeneca were trading up 0.6% at 4,416.00 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)